x.com· @ · X·· 2026-04-22Score60
Reading
KRAS / RAS targeting: from platform to Phase 3
daraxonrasib ± GnP · mono ORR 47%; +GnP ORR 55%, DCR 90%
Body
Our paper identifies pathways and proteins unique to #PancreaticCancer associated precancer lesions (cPanINs) versus incidental precancers (iPanINs).
Plus for the first time, proteomics of high grade PanIN lesions and acinar ductal metaplasia (ADM)!
#AACR26 https://t.co/KfjjKwxCLF
Heat 67 · 54 likes · 1 reply · 12 reposts
Source: x.com · x.com